Ming-Shi Chang
Chair Professor

Education and Research

Education

Ph.D., University of Texas Southwestern Medical Center, U.S.A.

Research Field

New drug discovery and development; the Human Genome Project; identifying novel molecular functions from the human gene library and developing new protein drugs for diseases such as cancer, cardiovascular disease, autoimmunity, and osteoporosis, or using stem cell therapy to achieve tissue regeneration.

Research Interests

The main goal of our lab's research projects is to screen the human genome project gene library for valuable new molecules, characterize their biological functions, and further develop them into new medicines. The scope of research includes cytokines, cytokine receptors, and chemokines. Through the development of these new molecules, we hope to treat diseases such as cancer, immune system disorders, cardiovascular disease, and osteoporosis.

We are also developing stem cell therapies for diseases such as stroke and renal failure.

Publications

1. Huang TH, Lewis JL, Lin HS, Kuo LT, Mao SW, Tai YS, Chang MS, Ables GP, Perrone CE, Yang RS. A methionine-restricted diet and endurance exercise decrease bone mass and extrinsic strength but increase intrinsic strength in growing male rats. J Nutr. 2014 [Abstract: Huang et al., 2014, J Nutr]
2. Hsu YH, Chang MS. The therapeutic potential of anti-interleukin-20 monoclonal antibody. Cell Transplant. 2014 [Abstract: Hsu et al., 2014, Cell Transplant]
3. Hsu YH, Li HH, Sung JM, Chen WT, Hou YC, Chang MS. Interleukin-19 mediates tissue damage in murine ischemic acute kidney injury. PLoS One. 2013 [Abstract: Hsu et al., 2013, PLoS One]
4. Hsu YH, Wei CC, Shieh DB, Chan CH, Chang MS. Anti-IL-20 monoclonal antibody alleviates inflammation in oral cancer and suppresses tumor growth. Mol Cancer Res. 2012 [Abstract: Hsu et al., 2012, Mol Cancer Res]
5. Hsu YH, Hsieh PP, Chang MS. Interleukin-19 blockade attenuates collagen-induced arthritis in rats. Rheumatology (Oxford). 2012 [Abstract: Hsu et al., 2012, Rheumatology (Oxford)]
6. Hsu YH, Hsing CH, Li CF, Chan CH, Chang MC, Yan JJ, Chang MS. Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models. J Immunol. 2012 [Abstract: Hsu et al., 2012, J Immunol]
7. Hsu YH, Chen WY, Chan CH, Wu CH, Sun ZJ, Chang MS. Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. J Exp Med. 2011 [Abstract: Hsu et al., 2011, J Exp Med]
8. Hsu YH, Chang MS. Interleukin-20 antibody is a potential therapeutic agent for experimental arthritis. Arthritis Rheum. 2010 [Abstract: Hsu et al., 2010, Arthritis Rheum]
9. Chen WY, Chang MS. IL-20 is regulated by hypoxia-inducible factor and up-regulated after experimental ischemic stroke. J Immunol. 2009 [Abstract: Chen et al., 2009, J Immunol]
10. Wei CC, Chang MS. Mouse interleukin-20 receptor 1a targets renal epithelial cells and is associated with renal calcium deposition. Genes Immun. 2009 [Abstract: Wei et al., 2009, Genes Immun]
11. Wei CC, Chang MS. A novel transcript of mouse interleukin-20 receptor acts on glomerular mesangial cells as an aggravating factor in lupus nephritis. Genes Immun. 2008 [Abstract: Wei et al., 2008, Genes Immun]
12. Li HH, Cheng HH, Sun KH, Wei CC, Li CF, Chen WC, Wu WM, Chang MS. Interleukin-20 targets renal mesangial cells and is associated with lupus nephritis. Clin Immunol. 2008 [Abstract: Li et al., 2008, Clin Immunol]
13. Wei CC, Li HH, Hsu YH, Hsing CH, Sung JM, Chang MS. Interleukin-20 targets renal cells and is associated with chronic kidney disease. Biochem Biophys Res Commun. 2008 [Abstract: Wei et al., 2008, Biochem Biophys Res Commun]
14. Huang KY, Lin RM, Chen WY, Lee CL, Yan JJ, Chang MS. IL-20 may contribute to the pathogenesis of human intervertebral disc herniation. Spine (Phila Pa 1976). 2008 [Abstract: Huang et al., 2008, Spine (Phila Pa 1976)]
15. Li HH, Hsu YH, Wei CC, Lee PT, Chen WC, Chang MS. Interleukin-20 induced cell death in renal epithelial cells and was associated with acute renal failure. Genes Immun. 2008 [Abstract: Li et al., 2008, Genes Immun]
16. Hsing CH, Chiu CJ, Chang LY, Hsu CC, Chang MS. IL-19 is involved in the pathogenesis of endotoxic shock. Shock. 2008 [Abstract: Hsing et al., 2008, Shock]
17. Hsing CH, Hsu CC, Chen WY, Chang LY, Hwang JC, Chang MS. Expression of IL-19 correlates with Th2 cytokines in uraemic patients. Nephrol Dial Transplant. 2007 [Abstract: Hsing et al., 2007, Nephrol Dial Transplant]
18. Huang KY, Yan JJ, Hsieh CC, Chang MS, Lin RM. The in vivo biological effects of intradiscal recombinant human bone morphogenetic protein-2 on the injured intervertebral disc: an animal experiment. Spine (Phila Pa 1976). 2007 [Abstract: Huang et al., 2007, Spine (Phila Pa 1976)]
19. Chen WY, Cheng BC, Jiang MJ, Hsieh MY, Chang MS. IL-20 is expressed in atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2006 [Abstract: Chen et al., 2006, Arterioscler Thromb Vasc Biol]
20. Hsu YH, Li HH, Hsieh MY, Liu MF, Huang KY, Chin LS, Chen PC, Cheng HH, Chang MS. Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum. 2006 [Abstract: Hsu et al., 2006, Arthritis Rheum]
21. Wei CC, Hsu YH, Li HH, Wang YC, Hsieh MY, Chen WY, Hsing CH, Chang MS. IL-20: biological functions and clinical implications. J Biomed Sci. 2006 [Abstract: Wei et al., 2006, J Biomed Sci]
22. Hsing CH, Ho CL, Chang LY, Lee YL, Chuang SS, Chang MS. Tissue microarray analysis of interleukin-20 expression. Cytokine. 2006 [Abstract: Hsing et al., 2006, Cytokine]
23. Wei CC, Chen WY, Wang YC, Chen PJ, Lee JY, Wong TW, Chen WC, Wu JC, Chen GY, Chang MS, Lin YC. Detection of IL-20 and its receptors on psoriatic skin. Clin Immunol. 2005 [Abstract: Wei et al., 2005, Clin Immunol]
24. Li HH, Lin YC, Chen PJ, Hsiao CH, Lee JY, Chen WC, Tzung TY, Wu JC, Chang MS. Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis. Br J Dermatol. 2005 [Abstract: Li et al., 2005, Br J Dermatol]
25. Chen WY, Cheng YT, Lei HY, Chang CP, Wang CW, Chang MS. IL-24 inhibits the growth of hepatoma cells in vivo. Genes Immun. 2005 [Abstract: Chen et al., 2005, Genes Immun]
26. Liao SC, Cheng YC, Wang YC, Wang CW, Yang SM, Yu CK, Shieh CC, Cheng KC, Lee MF, Chiang SR, Shieh JM, Chang MS. IL-19 induced Th2 cytokines and was up-regulated in asthma patients. J Immunol. 2004 [Abstract: Liao et al., 2004, J Immunol]
27. Wei CC, Ho TW, Liang WG, Chen GY, Chang MS. Cloning and characterization of mouse IL-22 binding protein. Genes Immun. 2003 [Abstract: Wei et al., 2003, Genes Immun]
28. Liao YC, Liang WG, Chen FW, Hsu JH, Yang JJ, Chang MS. IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol. 2002 [Abstract: Liao et al., 2002, J Immunol]
29. Senaldi G, Varnum BC, Sarmiento U, Starnes C, Lile J, Scully S, Guo J, Elliott G, McNinch J, Shaklee CL, Freeman D, Manu F, Simonet WS, Boone T, Chang MS. Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family. Proc Natl Acad Sci U S A. 1999 [Abstract: Senaldi et al., 1999, Proc Natl Acad Sci U S A]
30. Andrew DP, Chang MS, McNinch J, Wathen ST, Rihanek M, Tseng J, Spellberg JP, Elias CG 3rd. STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J Immunol. 1998 [Abstract: Andrew et al., 1998, J Immunol]
31. Chang MS, McNinch J, Elias C 3rd, Manthey CL, Grosshans D, Meng T, Boone T, Andrew DP. Molecular cloning and functional characterization of a novel CC chemokine, stimulated T cell chemotactic protein (STCP-1) that specifically acts on activated T lymphocytes. J Biol Chem. 1997 [Abstract: Chang et al., 1997, J Biol Chem]
32. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997 [Abstract: Simonet et al., 1997, Cell]
33. Chang MS, Hsu RY, McNinch J, Copeland NG, Jenkins NA. The gene for murine megakaryocyte growth and development factor (thrombopoietin, Thpo) is located on mouse chromosome 16. Genomics. 1995 [Abstract: Chang et al., 1995, Genomics]
34. Chang MS, McNinch J, Basu R, Shutter J, Hsu RY, Perkins C, Mar V, Suggs S, Welcher A, Li L, et al. Cloning and characterization of the human megakaryocyte growth and development factor (MGDF) gene. J Biol Chem. 1995 [Abstract: Chang et al., 1995, J Biol Chem]
35. Chang MS, McNinch J, Basu R, Simonet S. Cloning and characterization of the human neutrophil-activating peptide (ENA-78) gene. J Biol Chem. 1994 [Abstract: Chang et al., 1994, J Biol Chem]
36. Chang MS, Engel G, Benedict C, Basu R, McNinch J. Isolation and characterization of the human interleukin-9 receptor gene. Blood. 1994 [Abstract: Chang et al., 1994, Blood]

Patents

1. Ming-Shi Chang. Antibody to IL-20 and method for inhibiting IL-20 Induced cell proliferation. US Patent Number 7,435,800
2. Ming-Shi Chang. Anti-IL-20 antibody and its use in treating IL-20 associated inflammatory diseases. US Patent Number 7,611,705 B2
3. Ming-Shi Chang. Anti-IL-20 antibody and its use in treating IL-20 associated inflammatory diseases. US Patent Number 7,786,274
4. Ming-Shi Chang. Anti-IL-20 antibody and its use in treating IL-20 associated osteoporosis. US Patent Number 7,837,994
5. Ming-Shi Chang. Anti-IL-20 antibody and its use in treating stroke. US Patent Number 8,012,478
6. Ming-Shi Chang, David G. Lowe and David G. Goeddel. Composition and Methods for Synthesis of Natriuretic Protein Receptor B and Method of Use. US Patent Number 5,352,587
7. Ming-Shi Chang. A novel neurotrophic protein (NNT-1). US Patent Number 5,741,772
8. Ming-Shi Chang. Antibodies to the neurotrophic factor NNT-1. US Patent Number 6,143,874
9. Ming-Shi Chang. Nucleic acid molecules encoding the neurotrophic factor NNT-1. US Patent Number 6,054,294
10. Ming-Shi Chang, Bill Boyle, Frank Calzone and David Lacey. Osteoprotegerin. US Patent Number 6,015,938
11. Ming-Shi Chang, Bill Boyle, Frank Calzone and David Lacey. Osteoprotegerin. US Patent Number 6,613,544
12. Ming-Shi Chang, Bill Boyle, Frank Calzone and David Lacey. Osteoprotegerin. US Patent Number 6,369,027
13. Ming-Shi Chang, Bill Boyle, Frank Calzone and David Lacey. Osteoprotegerin. US Patent Number 6,288,032
14. Ming-Shi Chang, Bill Boyle, Frank Calzone and David Lacey. Osteoprotegerin. US Patent Number 6,284,740
15. Ming-Shi Chang, Bill Boyle, Frank Calzone and David Lacey. Osteoprotegerin. US Patent Number 6,284,728
16. Ming-Shi Chang, Bill Boyle, Frank Calzone and David Lacey. Osteoprotegerin. US Patent Number 6,284,485
17. Ming-Shi Chang, Bill Boyle, Frank Calzone and David Lacey. Osteoprotegerin. US Patent Number 7,005,413
18. Ming-Shi Chang, Bill Boyle, Frank Calzone and David Lacey. Osteoprotegerin. US Patent Number 7,632,922
19. Ming-Shi Chang and Christiaan Saris. Nucleic acid molecules encoding thymic stromal lymphopoietin receptor proteins and a process for producing the encoded polypeptides thereof. US Patent Number 7,964,713